Indian pharma producer Gufic Biosciences says it is looking at tapping generics and high-end life-saving products segment in emerging markets including Egypt, according to Business Standard. The company plans to provide high-end injections to the markets it is planning on penetrating at “a fraction of the current price.”
More from Enterprise
Our friends at EFG Hermes and Beltone pick up fresh accolades, along with CIB
EFG Hermes retained the top corporate access spot on Extel’s…
Granite is about to test whether Egypt’s funds still need administrators
The asset manager and blockchain builder Tarmiiz have entered the…
Inside the retail wave reshaping EGX
Individuals are setting EGX prices day to day, trading on…
Egyptian-UK fintech Zeal raises USD 10 mn to back expansion plans
The London-based, Egyptian-founded fintech is preparing to activate its loyalty…